Acute Myocarditis Registry With Prognostic, Histologic, Immunologic, Biological, Imaging and Clinical Assessment

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Apr 13, 2021

Keywords

ClinConnect Summary

The AMPHIBIA study is a clinical trial focused on understanding acute myocarditis, which is an inflammation of the heart muscle. Researchers want to learn more about the different features of this condition by looking at various tests and assessments, including imaging scans and blood tests. The goal is to see how these characteristics might affect the health outcomes of patients who are hospitalized with this condition. The trial is currently recruiting participants of all genders, aged 18 and older, who have been diagnosed with acute myocarditis using specific medical criteria.

To be eligible for the study, participants must have a confirmed diagnosis of acute myocarditis through heart imaging or a special biopsy of the heart tissue. They should also be part of the French health care system. However, people with certain heart conditions, such as severe valve disease or previous heart transplants, will not be able to participate. If you join the study, you can expect to undergo a series of assessments to help researchers gather important information about the disease and its effects on patients. This research could ultimately help improve the understanding and treatment of myocarditis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute myocarditis confirmed by cardiac magnetic resonance according to Lake Louise modified criteria or by endomyocardial biopsy according to histologic, immunologic and immunohistochemic criteria.
• • affiliation to the French Health Care System "Sécurité sociale"
• Exclusion Criteria:
• • Severe valvulopathy
• • Complex congenital cardiopathy
• • Previous heart transplant
• • Known significative coronary disease